Tango Therapeutics (TNGX) Preferred Stock Liabilities (2020 - 2021)
Tango Therapeutics (TNGX) recorded quarterly Preferred Stock Liabilities of $156.4 million in Q2 2021, little changed quarter-over-quarter from $157.1 million in Q1 2021.
Tango Therapeutics (TNGX) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Tango Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $156.4 million for Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Tango Therapeutics | 4.05 Bn | 3.67 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 156.36 Mn |
| Mar 31, 2021 | 157.12 Mn |
| Sep 30, 2020 | 157.43 Mn |